Puma Biotechnology, Inc.

Puma Biotechnology is a biopharmaceutical company focused on acquiring and developing novel therapeutics for the treatment of various forms of cancer. They specialize in in-licensing drug candidates that have completed or are undergoing initial clinical testing, aiming to further develop these candidates for commercial use. Their core focus lies in oncology, with a particular emphasis on HER2-positive breast cancer.

Puma Biotechnology has a strong track record of developing innovative therapies, including NERLYNX® (neratinib), a tyrosine kinase inhibitor approved for the treatment of HER2-positive breast cancer. They are actively pursuing clinical trials and research initiatives to expand the use of neratinib and investigate other promising drug candidates. Puma Biotechnology's dedication to advancing cancer treatments makes them a key player in the field of oncology.

Puma Biotechnology is a biopharmaceutical company focused on acquiring and developing innovative drug candidates for the treatment of various forms of cancer. They primarily seek out candidates that have already undergone initial clinical testing, aiming to further develop these drugs for commercial use and improve the lives of cancer patients.

Puma Biotechnology promotes a culture of scientific rigor and innovation, prioritizing the development of novel cancer treatments. Their website emphasizes their commitment to ethical practices, including adherence to industry standards for Independent Medical Education and a transparent approach to corporate governance. The company appears to value collaboration with healthcare professionals and researchers, and actively seeks to contribute to advancing medical knowledge and improving patient care.